EU/3/03/132

Table of contents

About

On 17 February 2003, orphan designation (EU/3/03/132) was granted by the European Commission to Combino Pharm, S.L., Spain, for caffeine citrate for the treatment of primary apnoea of premature newborns. The sponsorship was transferred to Chiesi Farmaceutici S.P.A., Italy, in January 2007.

Caffeine citrate has been authorised in the EU as Peyona (previously Nymusa) since 2 July 2009.

Key facts

Active substance
Caffeine citrate
Medicine name
Peyona
Disease / condition
Treatment of primary apnoea of premature newborns
Date of decision
17/02/2003
Outcome
Positive
Orphan decision number
EU/3/03/132

Sponsor's contact details

Chiesi Farmaceutici S.P.A.
Via Palermo 26/A
43100 Parma
Italy
Telephone: +39 05 21 27 97 10
Telefax: +39 05 21 77 41 20
E-mail: info@chiesigroup.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating